Amyloid PET and MRI in Alzheimer's disease and mild cognitive impairment

Current Alzheimer Research

Volumn 6, Issue 3, 2009, Pages 312-319

  Dimou, E ^a   Booij, J ^b   Rodrigues, M ^c   Prosch, H ^d   Attems, J ^d   Knoll, P ^c   Zajicek, B ^e   Dudczak, R ^a   Mostbeck, G ^d   Kuntner, C ^f   Langer, O ^f   Bruecke, T ^g   Mirzaei, S ^c  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c GENERAL HOSPITAL KLAGENFURT   (Austria)

^d OTTO WAGNER HOSPITAL   (Austria)

^e Texas Radiology Associates   (United States)

^f ARC SEIBERSDORF RESEARCH GMBH   (Austria)

^g WILHELMINEN HOSPITAL   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BAY 949172; BAY 949172 F 18; FLUORODEOXYGLUCOSE F 14; FLUORODEOXYGLUCOSE F 18; FLUOROETHYLMETHYLAMINONAPHTHYLETHYLIDENE MALONONITRILE F 18; INOSITOL; N ACETYLASPARTIC ACID; PITTSBURG COMPOUND B; RADIOPHARMACEUTICAL AGENT; TRACER; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BRAIN METABOLISM; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; EARLY DIAGNOSIS; GLUCOSE METABOLISM; HUMAN; MILD COGNITIVE IMPAIRMENT; NEUROFIBRILLARY TANGLE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT RESPONSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BENZOTHIAZOLES; BRAIN MAPPING; COGNITION DISORDERS; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; POSITRON-EMISSION TOMOGRAPHY;

EID: 67149108738     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720509788486563     Document Type: Review

References (95)

1. Alzheimer A. Über eine eigenartige Erkrankung der Hirnrinde. Allg Z Psychiatr Psychiatr Gerich Med 64: 146 (1907).
2. Hippius H, Müller N. The work of Emil Kraepelin and his research group in München. Eur Arch Psychiatry Clin Neurosci 258 (Suppl 2): 3-11 (2008). (Pubitemid 351758752)
3. Hardy J, Selkoe D. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-435 (2002). (Pubitemid 34790756)
4. Blennow K, de Leon M, Zetterberg H. Alzheimer's disease. Lancet 368: 387-403 (2006). (Pubitemid 44108123)
5. Rovelet-Lecrux A, Hannequin D, Raux G, Le Meur N, Laquerrière A, Vital A, et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 38 (1): 24-26 (2006).
6. Lovestone S, Reynolds CH. The phosphorylation of tau: a critical stage in neurodevelopment and neurodegenerative processes. Neuroscience 78: 309-324 (1997). (Pubitemid 27170324)
7. Mattson M. Pathways towards and away from Alzheimer's disease. Nature 430: 631-639 (2004). (Pubitemid 39061671)
8. Waldemar G, Dubois B, Emre M, Georges J, McKeith IG, Rossor M, et al. Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol 4(1): 1-26 (2007).
9. Braak H, Braak E. Development of Alzheimer-related neurofibrillary changes in the neocortex inversely recapitulates cortical myelogenesis. Acta Neuropathol 92: 197-201 (1996). (Pubitemid 26248463)
10. Petersen R, Smith GE, Waring S, Ivnik R, Tangalos E, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56: 760 (1999). (Pubitemid 29120227)
11. Petersen R. Mild cognitive impairment as a diagnostic entity. J Intern Med 256: 183-194 (2004). (Pubitemid 39222988)
12. Petersen R, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, et al. Current concepts in mild cognitive impairment. Arch Neurol 58: 1985-1992 (2001).
13. Förstl H, Kurz A. Clinical features of Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci 249: 288-290 (1999). (Pubitemid 30011730)
14. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-944 (1984). (Pubitemid 14076461)
15. Peterson A, Lantz M. American Association for Geriatric Psychiatry. Is it Alzheimer's? Neuropsychological testing helps to clarify diagnostic puzzle. Geriatrics 56: 58-61 (2001).
16. Fellows L, Bergman H, Wolfson C, Chertkow H. Can clinical data predict progression to dementia in amnestic mild cognitive impairment? Can J Neurol Sci 35: 314-322 (2008).
17. Zamrini E, De Santi S, Tolar M. Imaging is superior to cognitive testing for early diagnosis of Alzheimer's disease. Neurobiol Aging 25: 685-691 (2004). (Pubitemid 38686492)
18. Petrella J, Coleman R, Doraiswamy P. Neuroimaging and early diagnosis of Alzheimer disease: a look to the future. Radiology 226: 315-336 (2003). (Pubitemid 36313415)
19. Phelps M, Schelbert H, Mazziotta J. Positron computed tomography for studies of myocardial and cerebral function. Ann Intern Med 98: 339-359 (1983). (Pubitemid 13158508)
20. Rocher AB, Chapon F, Blaizot X, Baron JC, Chavoix C. Restingstate brain glucose utilization as measured by PET is directly related to regional synaptophysin levels: a study in baboons. Neuroimage 20: 1894-8 (2003). (Pubitemid 37468295)
21. Silverman D, Small G, Chang C, Lu C, Kung D, Aburto M, et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and longterm outcome. JAMA 286: 2120-2127 (2001).
22. Valla J, Berndt JD, Gonzalez-Lima F. Energy hypometabolism in posterior cingulate cortex of Alzheimer's patients: superficial laminar cytochrome oxidase associated with disease duration. J Neurosci 21: 4923-4930 (2001). (Pubitemid 32565651)
23. Nestor P, Fryer T, Smielewski P, Hodges J. Limbic hypometabolism in Alzheimer's disease and mild cognitive impairment. Ann Neurol 54: 343-351 (2003). (Pubitemid 37072036)
24. Mosconi L, Tsui W, De Santi S, Li J, Rusinek H, Convit A, et al. Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis. Neurology 64: 1860-7 (2005).
25. De Leon M, George A, Golomb J, Tarshish C, Convit A, Kluger A, et al. Frequency of hippocampal formation atrophy in normal aging and Alzheimer's disease. Neurobiol Aging 18: 1-11 (1997).
26. Okamura N, Arai H, Higuchi M, Tashiro M, Matsui T, Hu X, et al. [18F]FDG-PET study in dementia with Lewy bodies and Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 25: 447-456 (2001).
27. Minoshima S. Imaging Alzheimer's disease: clinical applications. Neuroimaging Clin N Am 13: 769-780 (2003). (Pubitemid 37445054)
28. Mazziotta J, Frackowiak R, Phelps M. The use of positron emission tomography in the clinical assessment of dementia. Semin Nucl Med 22: 233-246 (1992).
29. Salmon E, Sadzot B, Maquet P, Degueldre C, Lemaire C, Rigo P, et al. Differential diagnosis of Alzheimer's disease with PET. J Nucl Med 35: 391-398 (1994).
30. Small G. Positron emission tomography scanning for the early diagnosis of dementia. West J Med 171: 293-294 (1999).
31. Drzezga A, Grimmer T, Riemenschneider M, Lautenschlager N, Siebner H, Alexopoulus P, et al. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. J Nucl Med 46: 1625-1632 (2005).
32. Minoshima S, Giordani B, Berent S, Frey K, Foster N, Kuhl D. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 42: 85-94 (1997). (Pubitemid 27304784)
33. Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging 32: 486-510 (2005). (Pubitemid 40591181)
34. Herholz K, Nordberg A, Salmon E, Perani D, Kessler J, Mielke R, et al. Impairment of neocortical metabolism predicts progression in Alzheimer's disease. Dement Geriatr Cogn Disord 10: 494-504 (1999).
35. Drzezga A, Lautenschlager N, Siebner H, Riemenschneider M, Willoch F, Minoshima S, et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imaging 30: 1104-1113 (2003).
36. Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 129: 2856-2866 (2006).
37. Teipel SJ, Willoch F, Ishii K, Bürger K, Drzezga A, Engel R, et al. Resting state glucose utilization and the CERAD cognitive battery in patients with Alzheimer's disease. Neurobiol Aging 27: 681-690 (2006).
38. Desgranges B, Baron J, Lalevée C, Giffard B, Viader F, de La Sayette V, et al. The neural substrates of episodic memory impairment in Alzheimer's disease as revealed by FDG-PET: relationship to degree of deterioration. Brain 125: 1116-1124 (2002).
39. Nestor P, Fryer T, Hodges J. Declarative memory impairments in Alzheimer's disease and semantic dementia. Neuroimage 30: 1010-1020 (2006).
40. Grady C, McIntosh A, Beig S, Keightley M, Burian H, Black S. Evidence from functional neuroimaging of a compensatory prefrontal network in Alzheimer's disease. J Neurosci 23: 986-993 (2003). (Pubitemid 36206190)
41. Moeller JR, Ishikawa T, Dhawan V, Spetsieris P, Mandel F, Alexander G, et al. The metabolic topography of normal aging. J Cereb Blood Flow Metab 16: 385-398 (1996).
42. Nordberg A. PET imaging of amyloid in Alzheimer's disease. Lancet Neurol 3: 519-527 (2004). (Pubitemid 39485859)
43. Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol 45: 358-368 (1999).
44. Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer's disease. Am J Geriatr Psychiatry 10: 24-35 (2002).
45. Klunk W, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt D, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55: 306-319 (2004).
46. Maeda J, Ji B, Irie T, Tomiyama T, Maruyama M, Okauchi T, et al. Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. J Neurosci 27: 10957-10968 (2007).
47. Mathis C, Wang Y, Holt D, Huang G, Debnath M, Klunk W. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 46: 2740-2754 (2003). (Pubitemid 36702542)
48. Mathis C, Bacskai B, Kajdasz S, McLellan M, Frosch M, Hyman B, et al. A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg Med Chem Lett 12: 295-298 (2002).
49. Fagan A, Mintun M, Mach R, Lee S, Dence C, Shah A, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 59: 512-519 (2006).
50. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82: 239-259 (1991).
51. Rowe C, Ng S, Ackermann U, Gong S, Pike K, Savage G, et al. Imaging beta-amyloid burden in aging and dementia. Neurology 68: 1718-1725 (2007).
52. Mintun M, Larossa G, Sheline Y, Dence C, Lee S, Mach R, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 67: 446-452 (2006).
53. Buckner R, Snyder A, Shannon B, LaRossa G, Sachs R, Fotenos A, et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 25: 7709-7717 (2005).
54. Kemppainen N, Aalto S, Wilson I, Någren, Helin S, Brück A, et al. Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease. Neurology 67: 1575-1580 (2006).
55. Rabinovici G, Furst A, O'Neil J, Racine C, Mormino E, Baker S. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology 68: 1205-1212 (2007). (Pubitemid 46608468)
56. Engler H, Santillo AF, Wang SX, Lindau M, Savitcheva I, Nordberg A, et al. In vivo amyloid imaging with PET in frontotemporal dementia. Eur J Nucl Med Mol Imaging 35: 100-106 (2008).
57. Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 29: 1456-1465 (2008).
58. Colins F, (Ed). Foundation for the National Institutes of Health. Annual Report. p8 (http://www.fnih.org/images/stories/2007 annualreport.pdf) (2007).
59. Verhoeff N, Wilson A, Takeshita S, Trop L, Hussey D, Singh K, et al. In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. Am J Geriatr Psychiatry 12: 584-595 (2004).
60. Small G, Kepe V, Ercoli L, Siddarth P, Bookheimer S, Miller K, et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 355: 2652-2663 (2006).
61. Rowe C, Ackerman U, Browne W, Mulligan R, Pike KL, O'Keefe G, et al. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94- 9172, a novel PET tracer: proof of mechanism. Lancet Neurol 7: 129-135 (2008).
62. Edison P, Archer H, Hinz R, Hammers A, Pavese N, Tai YF, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology 68: 501-508 (2007).
63. Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 129: 2856-2866 (2006).
64. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. Correlative memory deficits, A beta elevation, and amyloid plaques in transgenic mice. Science 274: 99-102 (1996).
65. SturchlerPierrat C, Abramowski D, Duke M, Wiederhold K, Mistl C, Rothacher S, et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA 94: 13287-13292 (1997).
66. Klunk W, Lopresti B, Ikonomovic M, Lefterov I, Koldamova R, Abrahamson E, et al. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci 25: 10598-10606 (2005).
67. Toyama H, Ye D, Ichise M, Liow JS, Cai L, Jacobowitz D, et al. PET imaging of brain with the beta-amyloid probe, [11C]6-OHBTA-1, in a transgenic mouse model of Alzheimer's disease. Eur J Nucl Med Mol Imaging 32: 593-600 (2005).
68. Ye L, Morgenstern J, Lamb J, Lockhart A. Characterisation of the binding of amyloid imaging tracers to rodent A beta fibrils and rodent-human A beta co-polymers. Biochem Biophys Res Commun 347: 669-677 (2006). (Pubitemid 44109675)
69. Reiman E, Uecker A, Gonzalez-Lima F, Minear D, Chen K, Callaway N, et al. Tracking Alzheimer's disease in transgenic mice using fluorodeoxyglucose autoradiography. Neuroreport 11: 987-991 (2000).
70. Valla J, Schneider L, Reiman E. Age- and transgene-related changes in regional cerebral metabolism in PSAPP mice. Brain Res 1116: 194-200 (2006). (Pubitemid 44485010)
71. Kuntner C, Kesner A, Bauer M, Kremslehner R, Wanek T, Mandler M, et al. Limitations of small-animal PET imaging with [18F]FDDNP and [18F]FDG for quantitative studies in a transgenic mouse model of Alzheimer's disease. Mol Imaging Biol (2008); in press.
72. Dormont D, Seidenwurm DJ. Expert Panel on Neurologic Imaging; American College of Radiology. Dementia and movement disorders. Am J Neuroradiol 29: 204-206 (2008).
73. Scheltens P, Fox N, Barkhof F, De Carli C. Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion. Lancet Neurol 1: 13-21 (2002). (Pubitemid 37159194)
74. de Leon M, Golomb J, George A, Convit A, Tarshish C, McRae T, et al. The radiologic prediction of Alzheimer disease: the atrophic hippocampal formation. Am J Neuroradiol 14: 897-906 (1993).
75. Evans A. Large-scale morphometric analysis of neuroanatomy and neuropathology. Anat Embryol (Berl) 210: 439-446 (2005). (Pubitemid 41752605)
76. O'Brien JT. Role of imaging techniques in the diagnosis of dementia. Br J Radiol 80 (Spec No 2): S71-7 (2007). (Pubitemid 351799333)
77. Jack C, Petersen R, Xu Y, O'Brien P, Smith G, Ivnik R, et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 52: 1397-1403 (1999).
78. Karas G, Sluimer J, Goekoop R, van der Flier W, Rombouts SA, Vrenken H, et al. Amnestic mild cognitive impairment: structural MR imaging findings predictive of conversion to Alzheimer disease. Am J Neuroradiol 29: 944-949 (2008).
79. Nakada T, Matsuzawa H, Igarashi H, Fujii Y, Kwee IL. In vivo visualization of senile-plaque-like pathology in Alzheimer's disease patients by MR microscopy on a 7T system. J Neuroimaging 18: 125-129 (2008).
80. Norfray JF, Provenzale JM. Alzheimer's disease: neuropathologic findings and recent advances in imaging. Am J Roentgenol 182(1): 3-13 (2004). (Pubitemid 38017712)
81. Shonk T, Moats R, Gifford P, Michaelis T, Mandigo JC, Izumi J, et al. Probable Alzheimer disease: diagnosis with proton MR spectroscopy. Radiology 195(1): 65-72 (1995).
82. Ernst T, Chang L, Melchor R, Mehringer C. Frontotemporal dementia and early Alzheimer disease: differentiation with frontal lobe H-1 MR spectroscopy. Radiology 203(3): 829-836 (1997). (Pubitemid 27227438)
83. Bozzao A, Floris R, Baviera M, Apruzzese A, Simonetti G. Diffusion and perfusion MR imaging in cases of Alzheimer's disease: correlations with cortical atrophy and lesion load. Am J Neuroradiol 22: 1030-1036 (2001). (Pubitemid 32587412)
84. Teipel S, Meindl T, Grinberg L, Heinsen H, Hampel H. Novel MRI techniques in the assessment of dementia. Eur J Nucl Med Mol Imaging 35 (Suppl 1): S58-69 (2008).
85. Parente D, Gasparetto E, da Cruz L, Domingues R, Baptista A, Carvalho A, et al. Potential role of diffusion tensor MRI in the differential diagnosis of mild cognitive impairment and Alzheimer's disease. Am J Roentgenol 190: 1369-1374 (2008).
86. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-944 (1984). (Pubitemid 14076461)
87. Dubois B, Feldman H, Jacova C, Dekosky S, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6: 734-746 (2007).
88. Kovacs G, Alafuzoff I, Al-Sarraj S, Arzberger T, Bogdanovic N, Capellari S, et al. Mixed brain pathologies in dementia: the Brain- Net Europe consortium experience. Dement Geriatr Cogn Disord 26: 343-350 (2008).
89. Jack C, Lowe V, Senjem M, Weigand S, Kemp B, Shiung M, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 131: 665-680 (2008).
90. Pappatà S, Salvatore E, Postiglione A. In vivo imaging of neurotransmission and brain receptors in dementia. J Neuroimaging 18: 111-124 (2008).
91. Wu C, Cai L, Wei J, Pike VW, Wang Y. Lipophilic analogs of thioflavin S as novel amyloid-imaging agents. Curr Alzheimer Res 3: 259-266 (2006). (Pubitemid 43988139)
92. Hardy J, Seloke D. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-356 (2002). (Pubitemid 34790756)
93. Lahiri D, Chen D, Maloney B, Holloway H, Yu Q, Utsuki T, et al. The experimental Alzheimer's disease drug posiphen [(+)- phenserine] lowers amyloid-beta peptide levels in cell culture and mice. J Pharmacol Exp Ther 320: 386-396 (2007).
94. Kadir A, Andreasen N, Almkvist O, Wall A, Forsberg A, Engler H, et al. Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease. Ann Neurol 63: 621-631 (2008).
95. http://www.alzheimers.org.au/upload/ICAD2008biomarkers.pdf, ICAD (2008).